150 related articles for article (PubMed ID: 2880862)
81. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.
Schlechte J; el-Khoury G; Kathol M; Walkner L
J Clin Endocrinol Metab; 1987 May; 64(5):1021-6. PubMed ID: 3558723
[TBL] [Abstract][Full Text] [Related]
82. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome.
Cumming DC; Reid RL; Quigley ME; Rebar RW; Yen SS
Clin Endocrinol (Oxf); 1984 Jun; 20(6):643-8. PubMed ID: 6088126
[TBL] [Abstract][Full Text] [Related]
83. Gonadotropinic reserve in women affected by hyperprolactinemic amenorrhea.
Abate F; Oliva A; Baviera G; Martino P; Cannavò A; Leonardi R
Clin Exp Obstet Gynecol; 1980; 7(2):126-30. PubMed ID: 7018740
[TBL] [Abstract][Full Text] [Related]
84. Hyperprolactinemia: different clinical expression in childhood.
Saranac L; Zivanovic S; Radovanovic Z; Kostic G; Markovic I; Miljkovic P
Horm Res Paediatr; 2010; 73(3):187-92. PubMed ID: 20197671
[TBL] [Abstract][Full Text] [Related]
85. Dopamine is not involved in the opioid control of luteinizing hormone secretion in man.
Foresta C; Indino M; Federspil G; Scandellari C
Fertil Steril; 1985 Oct; 44(4):504-7. PubMed ID: 4054321
[TBL] [Abstract][Full Text] [Related]
86. Twenty-four hour secretory pattern of growth hormone in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
Endocrinol Jpn; 1987 Feb; 34(1):129-32. PubMed ID: 3608911
[TBL] [Abstract][Full Text] [Related]
87. [Functional hypothalamic amenorrheas. I. Physiopathology].
Gandar R; Collin D
J Gynecol Obstet Biol Reprod (Paris); 1993; 22(2):127-32. PubMed ID: 8514989
[TBL] [Abstract][Full Text] [Related]
88. Central opioid receptor activity in patients affected by puerperal, idiopathic and tumoral hyperprolactinemia.
De Leo V; Petraglia F; Sardelli S; De Leo M; Genazzani AR; D'Antona N
Gynecol Obstet Invest; 1985; 19(3):160-5. PubMed ID: 2991091
[TBL] [Abstract][Full Text] [Related]
89. The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls.
Golden NH; Pepper GM; Sacker I; Avruskin TW
J Adolesc Health; 1992 Mar; 13(2):155-60. PubMed ID: 1352703
[TBL] [Abstract][Full Text] [Related]
90. Neuroendocrine evaluation of central opiate activity in primary headache disorders.
Facchinetti F; Martignoni E; Gallai V; Micieli G; Petraglia F; Nappi G; Genazzani AR
Pain; 1988 Jul; 34(1):29-33. PubMed ID: 3043318
[TBL] [Abstract][Full Text] [Related]
91. Metoclopramide-induced hyperprolactinemia affects mouse endometrial morphology.
Rossi AG; Soares JM; Motta EL; Simões MJ; Oliveira-Filho RM; Haidar MA; Rodrigues de Lima G; Baracat EC
Gynecol Obstet Invest; 2002; 54(4):185-90. PubMed ID: 12592059
[TBL] [Abstract][Full Text] [Related]
92. [Hyperprolactinemia: etiology, clinical symptoms, and therapy].
Kałuzny M; Bolanowski M
Postepy Hig Med Dosw (Online); 2005; 59():20-7. PubMed ID: 15761382
[TBL] [Abstract][Full Text] [Related]
93. Marked augmentation of nocturnal melatonin secretion in amenorrheic athletes, but not in cycling athletes: unaltered by opioidergic or dopaminergic blockade.
Laughlin GA; Loucks AB; Yen SS
J Clin Endocrinol Metab; 1991 Dec; 73(6):1321-6. PubMed ID: 1955514
[TBL] [Abstract][Full Text] [Related]
94. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia.
Montejo ÁL; Arango C; Bernardo M; Carrasco JL; Crespo-Facorro B; Cruz JJ; Del Pino J; García Escudero MA; García Rizo C; González-Pinto A; Hernández AI; Martín Carrasco M; Mayoral Cleries F; Mayoral van Son J; Mories MT; Pachiarotti I; Ros S; Vieta E
Rev Psiquiatr Salud Ment; 2016; 9(3):158-73. PubMed ID: 26927534
[TBL] [Abstract][Full Text] [Related]
95. Normal lactotroph sensitivity to graded low-dose dopamine infusions in pathological hyperprolactinemia.
Ho KY; Smythe GA; Lazarus L
Neuroendocrinology; 1986; 43(2):175-81. PubMed ID: 3724984
[TBL] [Abstract][Full Text] [Related]
96. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea.
Biller BM; Baum HB; Rosenthal DI; Saxe VC; Charpie PM; Klibanski A
J Clin Endocrinol Metab; 1992 Sep; 75(3):692-7. PubMed ID: 1517356
[TBL] [Abstract][Full Text] [Related]
97. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma.
Seki K; Nagata I
Gynecol Obstet Invest; 1991; 31(4):222-5. PubMed ID: 1885092
[TBL] [Abstract][Full Text] [Related]
98. Childhood's enuresis in the history of women with hyperprolactinemic amenorrhea.
Fava M; Guaraldi GP; Borofsky GL; Mastrogiacomo I
Int J Psychiatry Med; 1989; 19(1):41-6. PubMed ID: 2722404
[TBL] [Abstract][Full Text] [Related]
99. Enhanced nocturnal melatonin secretion in women with functional secondary amenorrhea: relationship to opioid system and endogenous estrogen levels.
Okatani Y; Sagara Y
Horm Res; 1995; 43(5):194-9. PubMed ID: 7782049
[TBL] [Abstract][Full Text] [Related]
100. Opioid control of gonadotrophin secretion in humans.
Genazzani AR; Genazzani AD; Volpogni C; Pianazzi F; Li GA; Surico N; Petraglia F
Hum Reprod; 1993 Nov; 8 Suppl 2():151-3. PubMed ID: 8276950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
